Press Releases
Coming soon
At Alveus Therapeutics, we are building a differentiated therapeutic portfolio that delivers sustainable weight loss with superior tolerability, potentially improving patient outcomes, and addressing the critical challenge of weight maintenance that limits current treatments.
Explore our ScienceOur approach combines human genetic data, deep biological and clinical expertise, and rigorous program selection. We focus on targets with well-established human validation and clear mechanistic rationales to develop first- or best-in-class molecules that deliver transformative benefits in the evolving obesity treatment landscape.
More about scienceOur experienced leadership team brings proven success in metabolic disease drug development and pipeline building, backed by a Board with expertise across key functional areas.
Get to know our teamAlveus’s pipeline is focused on next-generation metabolic therapies; the lead asset ALV-100 is currently in Phase 2. The company’s preclinical amylin pipeline consists of best-in-class peptides, oral small molecules, and other novel formats targeting improved quality of weight loss.
View our pipeline